5-amino-1MQ, short for 5-amino-1-methylquinolinium, is a lab-made compound that blocks an enzyme called NNMT. Researchers study it in fat metabolism work, and it is often sold online next to peptides even though it is not one. This guide explains what 5-amino-1MQ is, how it works, what the early lab research reports, how it differs from NAD+ boosters, and why no human dose exists. It describes research only and is not advice for any person.
What Is 5-Amino-1MQ?
5-amino-1MQ is a small molecule, which means a compact chemical compound and not a protein-like chain. A peptide is a short chain of amino acids, the building blocks of proteins. 5-amino-1MQ is a ring-shaped chemical built on a quinolinium frame. The “amino” in its name refers to a small chemical group attached to the ring, not to a chain of amino acids. MK-677 is another compound that is sold alongside peptides but is not one.
A 2024 paper in Diabetes, Obesity and Metabolism describes it as a small-molecule NNMT inhibitor. It has not been approved as a medicine. The research behind it comes from cell studies and lab models, and the searches for this article found no published human trial of it.
How Does 5-Amino-1MQ Work?
An enzyme is a protein that speeds up a chemical reaction. NNMT, short for nicotinamide N-methyltransferase, is one of them. A 2021 review in Molecular Metabolism explains that NNMT adds a small chemical tag, called a methyl group, to nicotinamide, a form of vitamin B3. It uses a substance called SAM as the source of that tag.
Nicotinamide is also raw material for NAD+, a molecule cells use to run their energy systems. A 2025 paper in Physiological Reports describes NNMT as an enzyme that diverts precursors away from the NAD+ recycling pathway. In plain terms, NNMT drains some of the raw material cells need to make NAD+.
A 2014 paper in Nature found that NNMT activity was higher in fat tissue and liver in lab models of obesity and diabetes. When researchers turned NNMT down, the models resisted diet-induced obesity because their cells burned more energy, and NAD+ and SAM levels rose in fat tissue. That is the idea behind 5-amino-1MQ. It reaches NNMT inside the cell, and a 2018 paper in Biochemical Pharmacology found that this family of compounds passes easily through cell membranes.
The Molecular Metabolism review adds a caution. NNMT behaves differently by tissue. It appears to help regulate fats in the liver, while in fat tissue its level tracks with obesity and insulin resistance.
See also: Why Appetite Is a Bigger Research Puzzle Than Anyone Expected
What Early Research Reports
Online, 5-amino-1MQ is promoted for fat loss, muscle, and energy. The table shows what the research actually reports. Every finding comes from cell studies or lab models. None comes from people.
| Area studied | Status | What the research says |
|---|---|---|
| Fat gain and body weight | Lab models only | In lab models of diet-induced obesity, a potent NNMT inhibitor lowered body weight, white fat mass, fat cell size, and cholesterol (2018). No change in food intake was reported. |
| Fat loss with diet | Lab models only | With a low-fat diet, 5-amino-1MQ brought obese lab models to lean levels of fat and weight faster than the diet alone (2022). |
| Blood sugar and fatty liver | Lab models only | A 28-day study reported improved glucose tolerance and insulin sensitivity and less fatty liver change (2024). |
| Aging muscle | Lab models only | An NNMT inhibitor boosted muscle stem cell activity in aged lab models. Muscle fibers were nearly twice as large and peak force about 70 percent higher after injury (2019). A 2024 paper reported better grip strength in aging lab models. |
| Muscle strength in damaged limbs | Lab models only | In a 2025 model of poor limb blood flow, an NNMT inhibitor improved muscle strength without changing blood flow. |
| Fat loss or muscle gain in people | Not shown | No published human trial was found. |
The lab results are interesting, but they cannot be read as results for people.
See also: What Is Retatrutide? Mechanism, Research and Uses
How 5-Amino-1MQ Differs from NAD+ Precursors
NAD+ precursors such as NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are supplements that supply raw material for NAD+. 5-amino-1MQ takes a different route. Think of NAD+ as water in a bathtub. A precursor turns the tap on to add more water. An NNMT blocker tries to plug part of the drain so less is lost. Both aim for higher NAD+, but they act at different points.
| Feature | NAD+ precursors (NMN, NR) | 5-amino-1MQ |
|---|---|---|
| What it does | Adds raw material for NAD+ | Blocks NNMT, an enzyme that drains raw material |
| Type | Vitamin B3 related compounds | Lab-made small molecule |
| Human trials | Dozens, over weeks to months | None found |
| Evidence in people | Raises NAD+ levels, mixed results on function | Not studied |
The human record for precursors is a useful reality check. A 2023 review in The Journals of Gerontology says supplementation with NMN and NR is safe and tolerable and can raise NAD+ and related substances in many tissues, but evidence that this improves body function is unclear. A 2025 meta-analysis in the Journal of Cachexia, Sarcopenia and Muscle found no significant effect of NMN on muscle mass or function in adults over 60. A 2026 review in Ageing Research Reviews concluded that NAD+ boosting shows clear biological activity, but clinical benefit remains inconclusive. A 2024 review in Nature Reviews Molecular Cell Biology adds that much of NAD+ biology is poorly understood. Those cautions are worth keeping in mind for a blocker too. For more on NAD+ itself, see the NAD research guide.
See also: MK-677 Dosage Research and Handling Guide
Dosage in Published Research
There is no approved or proven dose of 5-amino-1MQ for people, and this guide does not recommend one. No human trial has been published, so there is nothing to base one on.
What exists is lab work. The 2024 paper gave 5-amino-1MQ once a day for 28 days and tested how it spreads through the body when given into the bloodstream, by mouth, and under the skin. It found high levels in fat, muscle, and liver after the under-the-skin route. Those weight-based amounts were set for lab models and cannot be converted into a figure for any person. Exact amounts quoted on retail, clinic, and directory sites do not come from human trials, so this guide does not repeat them.
Research material comes with a Certificate of Analysis and a handling sheet from the supplier. These list purity, contents, and storage conditions and are the main reference.
Frequently Asked Questions
Is 5-amino-1MQ a peptide?
No. It is a small, ring-shaped chemical compound. A peptide is a chain of amino acids.
Has 5-amino-1MQ been tested in people?
The searches for this article found no published human trial. A 2021 review said clinical trials targeting NNMT had not been reported, and a 2026 review says the safety profiles of NNMT inhibitors are still unknown.
Is 5-amino-1MQ the same as NMN?
No. NMN is a supplement that adds raw material for NAD+. 5-amino-1MQ blocks an enzyme that uses up that raw material.
How does it relate to SLU-PP-332?
Both are small molecules studied for metabolism, and neither is a peptide. They act on different targets. The SLU-PP-332 guide covers the other one.
Key Takeaways
- 5-amino-1MQ is a small molecule that blocks the enzyme NNMT. It is not a peptide.
- NNMT drains raw material that cells need for NAD+, which is why blocking it is studied.
- Lab models report less fat gain, better blood sugar handling, and stronger aged muscle, but no human trial exists.
- It works differently from NAD+ precursors such as NMN and NR, which are the ones that have been tested in people.
- No dose can be taken from this research, and long-term safety is unknown.
Research Use Disclaimer
This content is provided for Research Use Only (RUO). The compounds discussed are not drugs, dietary supplements, foods, or cosmetics, and are not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. They have not been evaluated by the FDA for safety or efficacy in humans. Any research use must be conducted by qualified professionals in a controlled laboratory environment, in accordance with all applicable institutional, local, and federal regulations.
Sources
- Roberti A, et al. Nicotinamide N-methyltransferase, at the crossroads between cellular metabolism and epigenetic regulation. Mol Metab. 2021.
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014.
- Dong G, et al. Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease. Physiol Rep. 2025.
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity. Biochem Pharmacol. 2018.
- Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol. 2019.
- Dimet-Wiley A, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in diet-induced obese models. Sci Rep. 2022.
- Babula JJ, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024.
- Liang R, et al. Identification of nicotinamide N-methyltransferase as a promising therapeutic target for sarcopenia. Aging Cell. 2024.
- Liu JR, et al. Roles of nicotinamide N-methyltransferase in obesity and type 2 diabetes. Biomed Res Int. 2021.
- Puleo N, et al. Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation. Trends Pharmacol Sci. 2026.
- Freeberg KA, et al. Dietary supplementation with NAD+-boosting compounds in humans, current knowledge and future directions. J Gerontol A Biol Sci Med Sci. 2023.
- Prokopidis K, et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function, a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2025.
- Gallagher C, et al. NAD+ supplementation for anti-aging and wellness, a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026.
- Migaud ME, et al. Regulation of and challenges in targeting NAD(+) metabolism. Nat Rev Mol Cell Biol. 2024.
Explore the weight loss research category for related research compounds.
